Baseline characteristics of the entire cohort based on patient-years. Values are % unless otherwise specified.
| Characteristic | Value |
|---|---|
| No. patient-yrs | 66,953 |
| Female sex | 81.6 |
| Age, yrs, mean ± SD | 62.7 ± 12.6 |
| Disease duration, yrs, median (IQR) | 10 (5–19) |
| DAS28-ESR, mean ± SD | 3.63 ± 1.36 |
| DAS28-CRP, mean ± SD | 2.92 ± 1.23 |
| Stage I/II/III/IV | 19/27/20/34 |
| Class 1/2/3/4 | 28/52/17/3 |
| Treated with NSAID | 57.6 |
| Treated with corticosteroids, dose, mg/week (median) | 54.1 (4.5) |
| Treated with MTX, dose, mg/week (median) | 52.9 (6) |
| Treated with anti-TNF biologics | 11.3 |
| Treated with non–anti-TNF biologics | 3.7 |
| Treated with any IS | 6.7 |
| Treated with tacrolimus | 6.0 |
Anti-TNF biologics consist of infliximab, etanercept, adalimumab, and golimumab. Non–anti-TNF biologics consist of tocilizumab and abatacept. Dose of corticosteroids was expressed in prednisolone equivalents. IS consist of tacrolimus, azathioprine, mizoribine, cyclophosphamide, and cyclosporine. IQR: interquartile range; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; Stage: Steinbrocker stage score; Class: global functional status; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; anti-TNF: anti-tumor necrosis factor; IS: immunosuppressants.